Showing results (391-400 of 401) with videos related to
Sort By:
Pageof 41
Cancer Chemotherapy and Pharmacology|August 28, 2016
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancerMuhammad Wasif Saif, James A Knost, E Gabriela Chiorean, et al.Anti-Cancer Drugs|June 14, 2011
Triphendiol (NV-196), development of a novel therapy for pancreatic cancerXiaohong Wang, Robert McKernan, Ki H Kim, et al.Cancer|September 14, 2016
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicityWen Wee Ma, Muhammad Wasif Saif, Bassel F El-Rayes, et al.Journal of Gastrointestinal Oncology|August 9, 2019
Medical record review of transition to lanreotide following octreotide for neuroendocrine tumorsMuhammad Wasif Saif, Rohan Parikh, David Ray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancerDiane Lauren Reidy, Efsevia Vakiani, Marwan G Fakih, et al.Cancer Chemotherapy and Pharmacology|June 7, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairmentMuhammad Wasif Saif, Carlos R Becerra, Marwan G Fakih, et al.Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.Pageof 41